This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MURA Mural Oncology (MURA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Mural Oncology Stock (NASDAQ:MURA) Get Mural Oncology alerts:Sign Up Key Stats Today's Range$2.04▼$2.0450-Day Range$2.02▼$2.1052-Week Range$1.53▼$2.98VolumeN/AAverage Volume227,153 shsMarket Capitalization$35.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Mural Oncology, Inc. (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents. Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection. Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development. The company’s interdisciplinary team combines expertise in oncology research, drug development and translational science to address unmet needs across multiple cancer indications.AI Generated. May Contain Errors. Read More Receive MURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mural Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MURA Stock News HeadlinesRecursion names Vicki Goodman as CMOMarch 25, 2026 | msn.comMural Oncology plc: Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | finanznachrichten.deElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.July 24 at 1:00 AM | Brownstone Research (Ad)Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | globenewswire.comMural Oncology Announces Sanction of the Scheme by the High CourtDecember 3, 2025 | globenewswire.comMural Oncology plc: Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyNovember 26, 2025 | finanznachrichten.deMural Oncology announces final cash consideration payable on acquisition closeNovember 26, 2025 | msn.comMural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyNovember 26, 2025 | globenewswire.comSee More Headlines MURA Stock Analysis - Frequently Asked Questions How were Mural Oncology's earnings last quarter? Mural Oncology PLC (NASDAQ:MURA) announced its earnings results on Thursday, November, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.38. What other stocks do shareholders of Mural Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mural Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings11/06/2025Today7/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MURA's financial health is in the Yellow zone, according to TradeSmith. MURA has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MURA Previous SymbolNASDAQ:MURA CIK1971543 Webwww.muraloncology.com Phone353-1-905-8020FaxN/AEmployees119Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$128.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-112.17% Return on Assets-89.37% Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book0.25Miscellaneous Outstanding Shares17,344,000Free Float16,962,000Market Cap$35.38 million OptionableOptionable Beta2.93 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MURA) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThis tiny piece of glass could be bigger than GPUsA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
